CoVPN 3502/REGN 2069: Regeneron’s REGEN-COV Antibody Cocktail

Read the latest news release: Regeneron Reports Positive Interim Data with REGEN-COV^TM Antibody Cocktail Used to Prevent COVID-19.

CoVPN 3502/REGN 2069 (The REACH Trial) is testing the combination of two antibodies (casirivimab and imdevimab antibody cocktail) ability to prevent acquisition of SARS-CoV-2. This study is enrolling approximately 3,500 adults and adolescents in North America and Europe who share a household with a person who has recently tested positive for SARS-CoV-2. Volunteers can be SARS-CoV-2 negative at enrollment or those who have acquired SARS-CoV-2 but do not have any COVID-19 symptoms. The REGEN-COV antibody cocktail are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. The REGEN-COV antibodies were made in a lab by the pharmaceutical company Regeneron. The REGEN-COV antibody cocktail cannot give you SARS-CoV-2, nor will they make you sick with COVID-19.

Learn more about the Regeneron monoclonal antibody clinical study and the antibodies used:

• Visit www.regeneron.com/covid19 or ClinicalTrials.gov - NCT04452318 for additional information about the study.
• Webcast: Regeneron COVID-19 Program Update, Sept. 29, 2020